Results 71 to 80 of about 14,556 (187)

The Role of Pharmacists in Tackling Mpox: Challenges and Future Prospects: A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Pharmacists play a key role in managing and mitigating mpox through clinical care, pharmacovigilance, vaccine management, and resilient supply chains. Management focuses on supportive care, infection prevention, and accurate diagnosis, with pharmacists ensuring the availability and rational use of vaccines, disinfectants ...
Ayalew Sirbemo Degebo, Fisseha Assegidew Gebretsadik, Abyou Seyfu Ambaye, Bedilu Linger Endalifer, Teshome Fentik Belachew   +4 more
wiley   +1 more source

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS

Рациональная фармакотерапия в кардиологии, 2018
Aim. To perform pharmacoeconomic analysis of CHF therapy with supramolecular sacubitril/valsartan complex compared to routine therapy in patients with diabetes type 2 and ACE inhibitor intolerance within context of Russian healthcare system.Material and ...
S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov   +2 more
doaj   +1 more source

Trimethoprim‐Sulfamethoxazole in the Treatment of Idiopathic Granulomatous Mastitis: A Retrospective Cohort Study

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Idiopathic Granulomatous Mastitis (IGM) is a rare, chronic inflammatory breast condition with uncertain etiology and challenging management. Standard treatments often involve corticosteroids or surgery, both associated with significant relapse and adverse effects.
Soheila Sayad, Saba Ahmadi, Mahdi Ahmadinia, Azadeh Eshraghi, Hamidreza Aslani, Maryam Farasatinasab   +5 more
wiley   +1 more source

A Claims-Based Algorithm for Identifying Hidradenitis Suppurativa Severity

Clinical Epidemiology
Maria C Schneeweiss,1– 3 Priyanka Anand,1,2 Arash Mostaghimi,2,3 Joan Landon,1,2 Denys Shay,1,4 Olivia MT Davies,2,3 Anusha Mohan Kumar,2,3 Aijing Shang,5 Tanja Tran,6 Robert J Glynn,1,2 Kueiyu Joshua Lin,1,2,7,8 Richard Wyss1,2 1Division of ...
Schneeweiss MC, Anand P, Mostaghimi A, Landon J, Shay D, Davies OMT, Kumar AM, Shang A, Tran T, Glynn RJ, Lin KJ, Wyss R   +11 more
doaj  

Active Safety Surveillance Using Real‐World Evidence (ASSURE) Implementation: Transparent and Reproducible Real‐World Evidence Standardized Framework to Support Safety Signal Evaluation

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
ABSTRACT Purpose To summarize experience with Johnson & Johnson's novel Active Safety Surveillance Using Real‐world Evidence (ASSURE) program for producing efficient, transparent, applicable, and impactful RWE to support routine pharmacovigilance processes.
Kevin Haynes, Jenna Reps, Jill Hardin, Eva‐Maria Didden, James Gilbert, Joel Swerdel, Justin Bohn, Mitchell M. Conover, Amir Sarayani, Anthony G. Sena, Emily Yost, Valerie van Baalen, Kourtney Davis, Patrick Ryan, Martijn Schuemie   +14 more
wiley   +1 more source

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study

The Prostate, Volume 86, Issue 11, Page 1233-1240, August 2026.
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma, Naoki Fujita, Shumon Kato, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Fumiya Yoneyama, Ryuma Tanaka, Takuya Oishi, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama   +18 more
wiley   +1 more source

Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study

Australasian Journal of Dermatology, Volume 67, Issue 5, Page 270-279, August 2026.
ABSTRACT Background/Objectives To estimate the lifetime and point prevalence of alopecia areata (AA) among Australians aged ≥ 15 years. Methods A cross‐sectional survey was conducted from August to September 2024 in a quota‐balanced sample of the Australian population, aged ≥ 12 years (exploratory objective included participants aged 12–14 years ...
Rodney Sinclair, Samantha Eisman, Leona Yip, Maureen Hitschfeld, Anna Williamson, Giles Stratton, Christoph Lohan, Carol M. Y. Lee, Komal Kapoor, Candida da Fonseca Pereira   +9 more
wiley   +1 more source

Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK‐air Study

Clinical &Experimental Allergy, Volume 56, Issue 8, Page 904-913, August 2026.
This mHealth study has shown that fixed combinations of intranasal antihistamines and corticosteroids were associated with higher quality of life than oral antihistamines and intranasal antihistamines. Both intranasal corticosteroids and oral antihistamines were associated with higher quality of life than intranasal antihistamines.
Nuno Lourenço‐Silva, Bernardo Sousa‐Pinto, Antonio Bognanni, Ana Margarida Pereira, João Coutinho‐Almeida, Rita Amaral, Luisa Brussino, Mattia Giovannini, Bilun Gemicioglu, Violeta Kvedariene, Desiree E. Larenas‐Linnemann, Manuel Marques‐Cruz, Nikolaos G. Papadopoulos, Nhân Pham‐Thi, Frederico S. Regateiro, Sanna K. Toppila‐Salmi, Boleslaw Samolinski, Joaquin Sastre, Luís Taborda‐Barata, Arunas Valiulis, Leticia de las Vecillas, Maria Teresa Ventura, Oliver Pfaar, João A. Fonseca, Torsten Zuberbier, Ludger Klimek, Jean Bousquet, Rafael José Vieira   +27 more
wiley   +1 more source

Risk Assessment for Complex Systems Based on Fuzzy Cognitive Maps: A Case of the Biopharmaceutical Industry

Complexity
Analyzing the supply chain (SC) of biopharmaceutical drugs can be challenging due to their complexity, the existence of a wide variety of risks, and the dynamics of the system.
Hadi Abbasian, Reza Yousefi-Zenouz, Abdollah Amirkhani, Masoud Shirzadeh, Akbar Abdollahiasl, Shekoufeh Nikfar, Mohammadreza Siahi-Shadabad, Abbas Kebriaeezadeh   +7 more
doaj   +1 more source

Data-Driven Vaccine Clinical Trial Design Features and Associated Progress Patterns: An Analysis of 1618 Clinical Trials from 2012 to 2022

Vaccines
Background/Objectives: Vaccine clinical trials face high costs, long timelines, and variable progression rates, yet systematic evidence linking trial design features to progression outcomes remains limited.
Siyang Chan, Dachuang Zhou, Di Zhang, Yuting Xia, Wenxi Tang   +4 more
doaj   +1 more source